AJP - Lung Columbus Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Lung Cell Mol Physiol 288: L1070-L1080, 2005. First published January 28, 2005; doi:10.1152/ajplung.00386.2004
1040-0605/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/6/L1070    most recent
00386.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tonks, A.
Right arrow Articles by Jackson, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tonks, A.
Right arrow Articles by Jackson, S. K.

Surfactant phospholipid DPPC downregulates monocyte respiratory burst via modulation of PKC

Alex Tonks,1 Joan Parton,2 Amanda J. Tonks,2 Roger H. K. Morris,3 Alison Finall,2 Kenneth P. Jones,3 and Simon K. Jackson2

Departments of 1Haematology and 2Medical Microbiology, School of Medicine, Wales College of Medicine, Cardiff University; and 3School of Applied Sciences, University of Wales Institute, Cardiff, United Kingdom

Submitted 13 October 2004 ; accepted in final form 21 January 2005

Pulmonary surfactant phospholipids have been shown previously to regulate inflammatory functions of human monocytes. This study was undertaken to delineate the mechanisms by which pulmonary surfactant modulates the respiratory burst in a human monocytic cell line, MonoMac-6 (MM6). Preincubation of MM6 cells with the surfactant preparations Survanta, Curosurf, or Exosurf Neonatal inhibited the oxidative response to either lipopolysaccharide (LPS) and zymosan or phorbol 12-myristate 13-acetate (PMA) by up to 50% (P < 0.01). Preincubation of MM6 cells and human peripheral blood monocytes with dipalmitoyl phosphatidylcholine (DPPC), the major phospholipid component of surfactant, inhibited the oxidative response to zymosan. DPPC did not directly affect the activity of the NADPH oxidase in a MM6 reconstituted cell system, suggesting that DPPC does not affect the assembly of the individual components of this enzyme into a functional unit. The effects of DPPC were evaluated on both LPS/zymosan and PMA activation of protein kinase C (PKC), a ubiquitous intracellular kinase, in MM6 cells. We found that DPPC significantly inhibited the activity of PKC in stimulated cells by 70% (P < 0.01). Western blotting experiments demonstrated that DPPC was able to attenuate the activation of the PKC{delta} isoform but not PKC{alpha}. These results suggest that DPPC, the major component of pulmonary surfactant, plays a role in modulating leukocyte inflammatory responses in the lung via downregulation of PKC, a mechanism that may involve the PKC{delta} isoform.

superoxide; signal transduction; dipalmitoyl phosphatidylcholine; inflammation; reactive oxygen intermediate



Address for reprint requests and other correspondence: A. Tonks, Dept. of Haematology (7th fl.), School of Medicine, Wales College of Medicine, Cardiff Univ., Heath Park, Cardiff CF14 4XN, UK (E-mail: tonksa{at}cf.ac.uk)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.